Seifert, Larissa
Zahner, Gunther
Meyer-Schwesinger, Catherine
Hickstein, Naemi
Dehde, Silke
Wulf, Sonia http://orcid.org/0000-0002-3169-0732
Köllner, Sarah M. S.
Lucas, Renke
Kylies, Dominik
Froembling, Sarah
Zielinski, Stephanie
Kretz, Oliver
Borodovsky, Anna
Biniaminov, Sergey
Wang, Yanyan
Cheng, Hong
Koch-Nolte, Friedrich
Zipfel, Peter F.
Hopfer, Helmut
Puelles, Victor G. http://orcid.org/0000-0002-7735-5462
Panzer, Ulf
Huber, Tobias B. http://orcid.org/0000-0001-7175-5062
Wiech, Thorsten http://orcid.org/0000-0003-4053-1474
Tomas, Nicola M. http://orcid.org/0000-0002-6385-9862
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (TO10-13, SFB1192)
Article History
Received: 7 June 2022
Accepted: 13 January 2023
First Online: 28 January 2023
Competing interests
: A.B. is an employee and shareholder of Alnylam Pharmaceuticals. P.F.Z. serves as a consultant for Eleva GMBH, Novartis, Generic Assays, Alexion, Bayer, Vifor Fresenius Medical Care Renal Pharma, and Samsung Bioepis. All other authors declare no competing interests. P.F., S.W., and T.W. applied for a patent “C3/C5 convertase assays” (EP 3771468/US-2022-0276261).